UNSPSC 51151649: Mepenzolate

This classification denotes an antimuscarinic agent with the molecular formula C21H26NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ONW3LB39P7, chemically known as 3-hydroxy-1, 1-dimethylpiperidinium bromide benzilate but generally known as mepenzolate, which bears US NIH Compound Identifier 4057. European Medicines Agency schedules Mepenzolate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14513MIG.

UNSPSC 51151649 Mepenzolate is a Commodity code that in recent state and local procurement activity captures pharmaceuticals and medical countermeasures for public health and emergency response, though the single recent solicitation shows a mismatch between the code's nominal scope and what is actually being bought. Seminole County, Florida issued IFB 60459723LAS seeking annual procurement of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems for community health initiatives, with quarterly deliveries to the county's Community Health Building. The code's narrow pharmaceutical focus does not align closely with the broader emergency-response and harm-reduction work reflected in that solicitation. State and local government buying under this code appears to target pharmaceutical inventory replenishment and public health supply chains, though the activity volume and breadth remain unclear from the single recent opportunity on record.

Seminole County represents the only recent issuing body captured in available records, limiting visibility into geographic spread or issuing-body mix across the code. The Naloxone and drug-deactivation-systems procurement was an IFB with a response deadline of July 26, 2023, and required vendors to provide unit costs, maintain standard insurance coverage including workers' compensation and commercial general liability, comply with drug-free workplace and E-Verify requirements, and accept a three-month probationary termination clause. The contract carried a two-year initial term with an optional one-year renewal and potential FEMA funding with corresponding federal compliance obligations. No explicit set-aside designations were specified. The scarcity of recent activity under this code and the narrow pharmaceutical scope suggest limited opportunity volume for business development purposes at this time.